Altered kynurenine pathway metabolism in autism: Implication for immune-induced glutamatergic activity

Chai K. Lim, Musthafa M. Essa, Roberta de Paula Martins, David B. Lovejoy, Ayse A. Bilgin, Mostafa I. Waly, Yahya M. Al-Farsi, Marwan Al-Sharbati, Mohammed A. Al-Shaffae, Gilles J. Guillemin

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

Dysfunction of the serotoninergic and glutamatergic systems is implicated in the pathogenesis of autism spectrum disorder (ASD) together with various neuroinflammatory mediators. As the kynurenine pathway (KP) of tryptophan degradation is activated in neuroinflammatory states, we hypothesized that there may be a link between inflammation in ASD and enhanced KP activation resulting in reduced serotonin synthesis from tryptophan and production of KP metabolites capable of modulating glutamatergic activity. A cross-sectional study of 15 different Omani families with newly diagnosed children with ASD (n = 15) and their age-matched healthy siblings (n = 12) was designed. Immunological profile and the KP metabolic signature were characterized in the study participants. Our data indicated that there were alterations to the KP in ASD. Specifically, increased production of the downstream metabolite, quinolinic acid, which is capable of enhancing glutamatergic neurotransmission was noted. Correlation studies also demonstrated that the presence of inflammation induced KP activation in ASD. Until now, previous studies have failed to establish a link between inflammation, glutamatergic activity, and the KP. Our findings also suggest that increased quinolinic acid may be linked to 16p11.2 mutations leading to abnormal glutamatergic activity associated with ASD pathogenesis and may help rationalize the efficacy of sulforaphane treatment in ASD. Autism Res 2016, 9: 621–631.

Original languageEnglish
Pages (from-to)621-631
Number of pages11
JournalAutism Research
Volume9
Issue number6
DOIs
Publication statusPublished - Jun 1 2016

Fingerprint

Kynurenine
Autistic Disorder
Quinolinic Acid
Inflammation
Tryptophan
Metabolic Networks and Pathways
Autism Spectrum Disorder
Synaptic Transmission
Siblings
Serotonin
Cross-Sectional Studies
Mutation

Keywords

  • autism
  • excitotoxicity
  • glutamatergic activity
  • kynurenine pathway
  • neuroinflammation
  • quinolinic acid

ASJC Scopus subject areas

  • Neuroscience(all)
  • Clinical Neurology
  • Genetics(clinical)

Cite this

Altered kynurenine pathway metabolism in autism : Implication for immune-induced glutamatergic activity. / Lim, Chai K.; Essa, Musthafa M.; de Paula Martins, Roberta; Lovejoy, David B.; Bilgin, Ayse A.; Waly, Mostafa I.; Al-Farsi, Yahya M.; Al-Sharbati, Marwan; Al-Shaffae, Mohammed A.; Guillemin, Gilles J.

In: Autism Research, Vol. 9, No. 6, 01.06.2016, p. 621-631.

Research output: Contribution to journalArticle

Lim, CK, Essa, MM, de Paula Martins, R, Lovejoy, DB, Bilgin, AA, Waly, MI, Al-Farsi, YM, Al-Sharbati, M, Al-Shaffae, MA & Guillemin, GJ 2016, 'Altered kynurenine pathway metabolism in autism: Implication for immune-induced glutamatergic activity', Autism Research, vol. 9, no. 6, pp. 621-631. https://doi.org/10.1002/aur.1565
Lim, Chai K. ; Essa, Musthafa M. ; de Paula Martins, Roberta ; Lovejoy, David B. ; Bilgin, Ayse A. ; Waly, Mostafa I. ; Al-Farsi, Yahya M. ; Al-Sharbati, Marwan ; Al-Shaffae, Mohammed A. ; Guillemin, Gilles J. / Altered kynurenine pathway metabolism in autism : Implication for immune-induced glutamatergic activity. In: Autism Research. 2016 ; Vol. 9, No. 6. pp. 621-631.
@article{84224ad2984e424d842dc6abe54f9bc6,
title = "Altered kynurenine pathway metabolism in autism: Implication for immune-induced glutamatergic activity",
abstract = "Dysfunction of the serotoninergic and glutamatergic systems is implicated in the pathogenesis of autism spectrum disorder (ASD) together with various neuroinflammatory mediators. As the kynurenine pathway (KP) of tryptophan degradation is activated in neuroinflammatory states, we hypothesized that there may be a link between inflammation in ASD and enhanced KP activation resulting in reduced serotonin synthesis from tryptophan and production of KP metabolites capable of modulating glutamatergic activity. A cross-sectional study of 15 different Omani families with newly diagnosed children with ASD (n = 15) and their age-matched healthy siblings (n = 12) was designed. Immunological profile and the KP metabolic signature were characterized in the study participants. Our data indicated that there were alterations to the KP in ASD. Specifically, increased production of the downstream metabolite, quinolinic acid, which is capable of enhancing glutamatergic neurotransmission was noted. Correlation studies also demonstrated that the presence of inflammation induced KP activation in ASD. Until now, previous studies have failed to establish a link between inflammation, glutamatergic activity, and the KP. Our findings also suggest that increased quinolinic acid may be linked to 16p11.2 mutations leading to abnormal glutamatergic activity associated with ASD pathogenesis and may help rationalize the efficacy of sulforaphane treatment in ASD. Autism Res 2016, 9: 621–631.",
keywords = "autism, excitotoxicity, glutamatergic activity, kynurenine pathway, neuroinflammation, quinolinic acid",
author = "Lim, {Chai K.} and Essa, {Musthafa M.} and {de Paula Martins}, Roberta and Lovejoy, {David B.} and Bilgin, {Ayse A.} and Waly, {Mostafa I.} and Al-Farsi, {Yahya M.} and Marwan Al-Sharbati and Al-Shaffae, {Mohammed A.} and Guillemin, {Gilles J.}",
year = "2016",
month = "6",
day = "1",
doi = "10.1002/aur.1565",
language = "English",
volume = "9",
pages = "621--631",
journal = "Autism Research",
issn = "1939-3806",
publisher = "John Wiley and Sons Inc.",
number = "6",

}

TY - JOUR

T1 - Altered kynurenine pathway metabolism in autism

T2 - Implication for immune-induced glutamatergic activity

AU - Lim, Chai K.

AU - Essa, Musthafa M.

AU - de Paula Martins, Roberta

AU - Lovejoy, David B.

AU - Bilgin, Ayse A.

AU - Waly, Mostafa I.

AU - Al-Farsi, Yahya M.

AU - Al-Sharbati, Marwan

AU - Al-Shaffae, Mohammed A.

AU - Guillemin, Gilles J.

PY - 2016/6/1

Y1 - 2016/6/1

N2 - Dysfunction of the serotoninergic and glutamatergic systems is implicated in the pathogenesis of autism spectrum disorder (ASD) together with various neuroinflammatory mediators. As the kynurenine pathway (KP) of tryptophan degradation is activated in neuroinflammatory states, we hypothesized that there may be a link between inflammation in ASD and enhanced KP activation resulting in reduced serotonin synthesis from tryptophan and production of KP metabolites capable of modulating glutamatergic activity. A cross-sectional study of 15 different Omani families with newly diagnosed children with ASD (n = 15) and their age-matched healthy siblings (n = 12) was designed. Immunological profile and the KP metabolic signature were characterized in the study participants. Our data indicated that there were alterations to the KP in ASD. Specifically, increased production of the downstream metabolite, quinolinic acid, which is capable of enhancing glutamatergic neurotransmission was noted. Correlation studies also demonstrated that the presence of inflammation induced KP activation in ASD. Until now, previous studies have failed to establish a link between inflammation, glutamatergic activity, and the KP. Our findings also suggest that increased quinolinic acid may be linked to 16p11.2 mutations leading to abnormal glutamatergic activity associated with ASD pathogenesis and may help rationalize the efficacy of sulforaphane treatment in ASD. Autism Res 2016, 9: 621–631.

AB - Dysfunction of the serotoninergic and glutamatergic systems is implicated in the pathogenesis of autism spectrum disorder (ASD) together with various neuroinflammatory mediators. As the kynurenine pathway (KP) of tryptophan degradation is activated in neuroinflammatory states, we hypothesized that there may be a link between inflammation in ASD and enhanced KP activation resulting in reduced serotonin synthesis from tryptophan and production of KP metabolites capable of modulating glutamatergic activity. A cross-sectional study of 15 different Omani families with newly diagnosed children with ASD (n = 15) and their age-matched healthy siblings (n = 12) was designed. Immunological profile and the KP metabolic signature were characterized in the study participants. Our data indicated that there were alterations to the KP in ASD. Specifically, increased production of the downstream metabolite, quinolinic acid, which is capable of enhancing glutamatergic neurotransmission was noted. Correlation studies also demonstrated that the presence of inflammation induced KP activation in ASD. Until now, previous studies have failed to establish a link between inflammation, glutamatergic activity, and the KP. Our findings also suggest that increased quinolinic acid may be linked to 16p11.2 mutations leading to abnormal glutamatergic activity associated with ASD pathogenesis and may help rationalize the efficacy of sulforaphane treatment in ASD. Autism Res 2016, 9: 621–631.

KW - autism

KW - excitotoxicity

KW - glutamatergic activity

KW - kynurenine pathway

KW - neuroinflammation

KW - quinolinic acid

UR - http://www.scopus.com/inward/record.url?scp=84974784672&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84974784672&partnerID=8YFLogxK

U2 - 10.1002/aur.1565

DO - 10.1002/aur.1565

M3 - Article

C2 - 26497015

AN - SCOPUS:84974784672

VL - 9

SP - 621

EP - 631

JO - Autism Research

JF - Autism Research

SN - 1939-3806

IS - 6

ER -